RxDoctor Payments Data

Salvatore Tarantino, MD

Internal Medicine · la Mesa, CANPI 1174581458

Payments from drug & device makers

$6,231in general payments, 2019–2025

Across 336 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$817
  • Boehringer Ingelheim$715
  • AbbVie$594
  • Novo Nordisk$580
  • AstraZeneca$552
  • Pfizer$528
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$6,219100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,231 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$136,770
Medicare patients
279
Services billed
8,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$131,266
OzempicSemaglutide98$111,844
JardianceEmpagliflozin81$109,516
XareltoRivaroxaban74$86,240
RybelsusSemaglutide28$53,469
FarxigaDapagliflozin Propanediol48$52,192
MounjaroTirzepatide42$48,914
TrulicityDulaglutide39$48,060
ProliaDenosumab21$36,936
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$32,930
EntrestoSacubitril/Valsartan21$23,524
JanuviaSitagliptin Phosphate21$18,078
Bydureon BciseExenatide Microspheres13$10,793
LinzessLinaclotide12$8,487
Atorvastatin Calcium807$8,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$580$165,312126 claims
PfizerEliquis$528$131,266110 claims
Boehringer IngelheimJardiance$715$109,51681 claims
Lilly USA, LLCMounjaro, Trulicity$817$96,97481 claims
Johnson & JohnsonXarelto$171$86,24074 claims
AstraZenecaFarxiga$552$52,19248 claims
AmgenProlia$180$36,93621 claims
GSKTrelegy Ellipta$97$32,93035 claims
NovartisEntresto$121$23,52421 claims
MerckJanuvia$140$18,07821 claims
AbbVieLinzess$594$8,48712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →